ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Radiotherapy and DNA damage response inhibitors modestly sensitize HNSCC to NK cell killing, with ATM inhibition more effective than ATR inhibition.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHuman papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC) remain challenging due to their reduced radiosensitivity. Targeting the DNA damage response (DDR) with kinase inhibitors may enhance tumor susceptibility to radiotherapy (RT). While RT is known to alter the immune phenotype of HNSCC cells, its impact on innate immune responses, particularly on natural killer (NK) cells, remains unclear. We therefore investigated how RT combined with ATM or ATR inhibition-key DDR kinases-affects NK cell-mediated killing and activation.
methodsThe tumor cell lines HSC4 and Cal33 (both HPV-negative) and UM-SCC-47 and UD-SCC‑2 (both HPV-positive) were treated with the DDR inhibitors VE-822 (ATRi) and AZD0156 (ATMi) and hypofractionated RT (2 × 5 Gy). After co-cultivation with primary human NK cells, tumor cell death was measured using flow cytometry after 24 h. Further, NK cell activation markers and the supernatant of tumor cell-NK cell co-cultures were measured and the effect of immune checkpoint inhibitors (durvalumab, monalizumab) was additionally investigated.
resultsParticularly the HPV-negative HSC4 cells pretreated with either ATMi or RT + ATMi showed significantly increased killing by NK cells. Reduced secretion of granulysin by NK cells was mainly found in the co-cultures of HPV-negative HNSCC treated with ATRi. Treatment with the immune checkpoint inhibitor durvalumab (anti-PD-L1) did not result in significant augmentation of NK cell-induced tumor cell killing in this setting. Conversely, treatment with monalizumab (anti-NKG2A) resulted in a modest increase.
conclusionNatural killer cells showed only a limited contribution to the killing of HNSCC cells pretreated with RT or RT + DDRi. However, a subset of patients with head and neck tumors-such as those represented by the HSC4 model-might still benefit from combining RT with ATMi rather than ATRi to enhance NK cell-mediated tumor killing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.